Slow releasing anticancer drug containing CDDP for intraoperative use in residual cancer cells
Suzuki, K.; Matsuura, H.; Yoshimura, H.; Koto, T.; Tabara, H.; Nakamura, T.; Kifune, K.; Tsurutani, R.; Yoshimura, M.; Nakamura, Y.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(10 Suppl): 1728-1730
1992
ISSN/ISBN: 0385-0684 PMID: 1530342 Document Number: 393280
We have already reported the slow releasing property and anticancer effect of Plachitin, which is reconstituted by combination of CDDP and chitin. This study deals in more detail with the slow releasing property, and the renal complications and the effectiveness for solid tumor were examined. After implantation of Plachitin subcutaneously in the abdominal wall, the platinum concentration in the different organs was measured. In the abdominal muscle around the implanted Plachitin, a high concentration of platinum was maintained until 8 weeks and the peak was 4 weeks after implantation. At the same time, the serum concentration of platinum remained low. In kidney, the platinum concentration resembled the levels in the abdominal muscle, but no renal dysfunction was found serologically or histologically. When Plachitin was implanted around the solid tumor, the survival rates were improved and the gain in tumor weight was suppressed as compared with the controls. From these findings, Plachitin seemed to be effective as a slow releasing anticancer drug for topical application.